EDIRX Mutual Fund

NAV$12.43

Fund Essentials - as of Jan 31, 2026

Net Assets
-
Expense Ratio
1.42%
Dividend Yield (Current)
4.72%
Holdings
601
Inception Date
Jan 31, 2006
Fund Family
Eaton Vance
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Monthly
SEC 30-Day Yield
PRO

Performance

YTD+7.09%
1 Year+16.43%
3 Year+14.05%
5 Year+7.31%
10 Year+8.64%

Asset Allocation

Stocks: 63.96%
Bonds: 35.64%
Cash: 0.27%
Other: 0.13%

Price Chart (6M)

Loading chart data...

Top Holdings

View All →
TickerNameWeight
GOOGAlphabet Inc. C3.81%
LLYEli Lilly & Co2.64%
MSFTMicrosoft Corp 4.100 Feb 06 372.51%
MUMicron Technology, Inc.2.51%
NVDANvidia Corp.2.23%
Top 10 Concentration: 21.79%Report Date: Jan 31, 2026
Download all 601 holdings for EDIRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
4.72%
Frequency
Monthly
Latest Distribution
$0.03
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how EDIRX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

EDIRX Mutual Fund Overview

EDIRX Mutual Fund (Eaton Vance Global Income Builder Fund Class R) is managed by Eaton Vance. EDIRX expense ratio is 1.42%, holding 601 positions across sectors including Unknown, Other, Information Technology. Inception date: 2006-01-31.

EDIRX performance shows a YTD return of 7.09%. The 1-year return is 16.43% and the 5-year return is 7.31%. EDIRX dividend yield stands at 4.72%, paid monthly.

EDIRX top holdings include Alphabet Inc. C (3.8%), Eli Lilly & Co (2.6%), Microsoft Corp 4.100 Feb 06 37 (2.5%), Micron Technology, Inc. (2.5%), Nvidia Corp. (2.2%). View all EDIRX holdings, sector breakdown, or dividend history.

EDIRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. EDIRX alternatives are available via the screener, along with tax-loss harvesting opportunities.